Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Malin, Hagberg Thulin"'
Autor:
Riikka Huhtaniemi, Petra Sipilä, Arttu Junnila, Riikka Oksala, Matias Knuuttila, Arfa Mehmood, Eija Aho, Teemu D. Laajala, Tero Aittokallio, Asta Laiho, Laura Elo, Claes Ohlsson, Malin Hagberg Thulin, Pekka Kallio, Sari Mäkelä, Mika V.J. Mustonen, Matti Poutanen
Publikováno v:
iScience, Vol 25, Iss 5, Pp 104287- (2022)
Summary: Antiandrogen treatment resistance is a major clinical concern in castration-resistant prostate cancer (CRPC) treatment. Using xenografts of VCaP cells we showed that growth of antiandrogen resistant CRPC tumors were characterized by a higher
Externí odkaz:
https://doaj.org/article/125d518783f44b70a3bc79f19094057c
Autor:
Tom A. Bäck, Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, Holger Jensen, Tove Olafsen, Paul J. Yazaki, Stig Palm, Per Albertsson, Jan-Erik Damber, Anna M. Wu, Karin Welén
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-12 (2020)
Abstract Purpose Targeted alpha therapy (TAT) is a promising treatment for micrometastatic and minimal residual cancer. We evaluated systemic α-radioimmunotherapy (α-RIT) of metastatic castration-resistant prostate cancer (mCRPC) using the α-parti
Externí odkaz:
https://doaj.org/article/cb79622cfe444d258013759e1047e094
Autor:
Jan-Erik Damber, Claes Ohlsson, Anna Linder, Anders Widmark, Simona Sterbova, Jorma A. Määttä, Malin Hagberg Thulin, Emma Persson
Publikováno v:
The Prostate. 81:452-462
Background Prostate cancer (PC) metastasizes to the skeleton forming predominantly sclerotic lesions, and there is currently no cure for bone metastatic disease. The transcription factor signal transducer and activator of transcription 3 (STAT3) is i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb7c3de37b1bd41bbb0c5f961607d407
https://doi.org/10.1002/pros.24125
https://doi.org/10.1002/pros.24125
Autor:
Sture Lindegren, Karin Jennbacken, Jan-Erik Damber, Holger Jensen, Karin Welén, Malin Hagberg Thulin, Anna M. Wu, Per Albertsson, Paul J. Yazaki, Stig Palm, Tove Olafsen, Tom Bäck
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-12 (2020)
EJNMMI Research
EJNMMI Research
Purpose Targeted alpha therapy (TAT) is a promising treatment for micrometastatic and minimal residual cancer. We evaluated systemic α-radioimmunotherapy (α-RIT) of metastatic castration-resistant prostate cancer (mCRPC) using the α-particle emitt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f2d45f10c4f8a600d65d1e9f9ddbcd4
https://doaj.org/article/cb79622cfe444d258013759e1047e094
https://doaj.org/article/cb79622cfe444d258013759e1047e094
Publikováno v:
Molecular and Cellular Endocrinology. 535:111380
Intratumoral steroidogenesis is involved in development of castration-resistant prostate cancer (CRPC) as bone metastases. The osteoblast transcription factor RUNX2 influences steroidogenesis and is induced in CRPC cells by osteoblasts. This study in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0397ca62afa88f2ee5e2fd16a5e67499
https://doi.org/10.1016/j.mce.2021.111380
https://doi.org/10.1016/j.mce.2021.111380
Autor:
Claes Ohlsson, Karin Welén, Pontus Thulin, Jocelyn Céraline, Jan-Erik Damber, Malin Hagberg Thulin, Maria E. Nilsson
Publikováno v:
Molecular and Cellular Endocrinology. 422:182-191
The skeleton is the preferred site for prostate cancer (PC) metastasis leading to incurable castration-resistant disease. The increased expression of genes encoding steroidogenic enzymes found in bone metastatic tissue from patients suggests that up-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81de622460b6f5371cf8297fb753aebc
https://doi.org/10.1016/j.mce.2015.11.013
https://doi.org/10.1016/j.mce.2015.11.013
Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment
Autor:
Malin Hagberg Thulin, Lisa U. Magnusson, Pascale Plas, Karin Welén, Anders Olsson, Jan-Erik Damber
Publikováno v:
The Prostate. 76:383-393
BACKGROUND Tasquinimod (ABR-215050) is an orally active quinoline-3-carboxamide analog that inhibits occurrence of experimental metastasis and delays disease progression of castration resistant prostate cancer in humans. Its mechanism of action is no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cf6ddb343c099fd6bae3587c0b7fd12
https://doi.org/10.1002/pros.23133
https://doi.org/10.1002/pros.23133
Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment
Autor:
Lisa U, Magnusson, Malin, Hagberg Thulin, Pascale, Plas, Anders, Olsson, Jan-Erik, Damber, Karin, Welén
Publikováno v:
The Prostate. 76(4)
Tasquinimod (ABR-215050) is an orally active quinoline-3-carboxamide analog that inhibits occurrence of experimental metastasis and delays disease progression of castration resistant prostate cancer in humans. Its mechanism of action is not fully elu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c0aefc2ee4a4d084079c79e0c322d27f
https://pubmed.ncbi.nlm.nih.gov/26660725
https://pubmed.ncbi.nlm.nih.gov/26660725
Publikováno v:
Clinical & Experimental Metastasis
Castration-resistant prostate cancer (CRPC) is strongly associated with sclerotic bone metastases and poor prognosis. Models that mimic human CRPC are needed to identify the mechanisms for prostate cancer (PC) growth in bone and to develop new therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daae32f60616be381919ee4defa2264d
https://pubmed.ncbi.nlm.nih.gov/24292404
https://pubmed.ncbi.nlm.nih.gov/24292404